S&CO Inc. Buys 4,762 Shares of Humana Inc. (NYSE:HUM)

S&CO Inc. lifted its position in Humana Inc. (NYSE:HUM - Free Report) by 16.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 33,760 shares of the insurance provider's stock after acquiring an additional 4,762 shares during the period. S&CO Inc.'s holdings in Humana were worth $10,693,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Mendota Financial Group LLC increased its position in Humana by 9.2% during the 2nd quarter. Mendota Financial Group LLC now owns 319 shares of the insurance provider's stock valued at $119,000 after buying an additional 27 shares in the last quarter. Capital Advisors Ltd. LLC increased its holdings in shares of Humana by 17.0% during the second quarter. Capital Advisors Ltd. LLC now owns 213 shares of the insurance provider's stock valued at $80,000 after acquiring an additional 31 shares in the last quarter. CarsonAllaria Wealth Management Ltd. raised its position in shares of Humana by 111.4% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider's stock worth $28,000 after purchasing an additional 39 shares during the last quarter. Harbour Investments Inc. boosted its stake in Humana by 10.5% in the 2nd quarter. Harbour Investments Inc. now owns 432 shares of the insurance provider's stock worth $161,000 after purchasing an additional 41 shares in the last quarter. Finally, Baader Bank Aktiengesellschaft grew its position in Humana by 1.0% during the 2nd quarter. Baader Bank Aktiengesellschaft now owns 4,421 shares of the insurance provider's stock valued at $1,649,000 after purchasing an additional 42 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors.

Humana Stock Performance

Shares of HUM stock traded down $7.47 during trading hours on Friday, reaching $275.67. 1,842,901 shares of the company traded hands, compared to its average volume of 2,301,719. The firm has a 50-day moving average price of $281.36 and a 200 day moving average price of $331.94. The company has a market cap of $33.19 billion, a P/E ratio of 24.42, a P/E/G ratio of 2.17 and a beta of 0.52. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $527.18. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, beating the consensus estimate of $3.48 by $0.68. The business had revenue of $29.30 billion for the quarter, compared to the consensus estimate of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. As a group, sell-side analysts predict that Humana Inc. will post 15.86 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be issued a dividend of $0.885 per share. The ex-dividend date is Tuesday, December 31st. This represents a $3.54 dividend on an annualized basis and a yield of 1.28%. Humana's dividend payout ratio is presently 31.36%.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Truist Financial dropped their target price on shares of Humana from $400.00 to $260.00 and set a "hold" rating on the stock in a research note on Friday, October 11th. Royal Bank of Canada lowered their price objective on Humana from $400.00 to $265.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 8th. Oppenheimer reduced their target price on Humana from $400.00 to $280.00 and set an "outperform" rating for the company in a report on Thursday, October 3rd. Deutsche Bank Aktiengesellschaft decreased their price target on Humana from $349.00 to $250.00 and set a "hold" rating for the company in a research note on Thursday, October 3rd. Finally, Barclays increased their price objective on Humana from $250.00 to $253.00 and gave the company an "equal weight" rating in a research report on Thursday, October 31st. Twenty research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, Humana has a consensus rating of "Hold" and an average target price of $315.86.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.